Objective. The objective of this study was to measure cumulative incidence and incidence rate and identify factors associated with new musculoskeletal (MSK) symptomatic areas after total knee replacement (TKR) for osteoarthritis (OA).
INTRODUCTION
With roughly 723 000 primary total knee replacements (TKRs) performed annually in the United States, postoperative outcomes have been a major focus of research in the field of knee osteo arthritis (OA) (1) . A number of preoperative factors have already been implicated as predictors of adverse postoperative out comes, including age, sex, preoperative pain and function, socio economic status, anxiety, and depression (2) (3) (4) . Recognition of these predictors has enabled health care providers to better iden tify candidates for TKR and tailor preoperative counseling accord ing to the needs of the patient.
One risk factor of recent interest has been the presence of concomitant musculoskeletal (MSK) complaints (5) (6) (7) . To date, literature on the effects of concomitant MSK complaints on TKR outcomes has been focused on preoperative MSK complaints. For example, Kahn et al (5) reported that preoperative Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, disability, and stiffness scores in the contralateral knee were correlated, although moderately, with worse post-TKR WOMAC total scores in the index knee (r = 0.34; P < 0.001).
Similarly, Perruccio et al (6) showed that patients with pre existing neck, ankle, feet, or toe pain had statistically significant worse postoperative WOMAC pain scores compared with those without preexisting pain. Those with preoperative total painful joint counts of 4 or greater reported worse pain outcome scores postoperatively (6) . Subjects with higher baseline WOMAC pain scores or with anxiety and depression were more likely to have these preoperative MSK complaints (6) . Finally, Collados-Maestre et al (7) demonstrated that patients with concomitant presurgical lower back pain had worse postsurgical WOMAC, Short-Form 12, visual analogue scale for satisfaction, and functional Knee Soci ety scores. These studies suggest that preoperative MSK symp tomatic areas are associated with worse self-reported pain and self-reported functional outcomes after TKR.
Beyond preoperative joint complaints, however, no stud ies have examined the development of new MSK symptomatic areas occurring after TKR. If present, these symptomatic areas could contribute to the overall level of pain and functional limita tion post-TKR, ultimately creating new barriers to optimal recovery and delaying proper rehabilitation. Such limitations could also lead to greater postoperative patient dissatisfaction. By understanding the risk factors for incident MSK symptomatic areas, health care providers can adapt their preoperative conversations to offer real istic patient expectations.
In this report, we aimed to document the cumulative inci dence and incidence rate of self-reported MSK symptomatic areas during 4 years of follow-up after unilateral TKR for OA. We also identified preoperative factors associated with the develop ment of postoperative MSK symptomatic areas. We hypothesized that self-reported MSK symptomatic areas would occur frequently after unilateral TKR and that risk factors for these incident symp tomatic areas would include higher baseline WOMAC pain scores and feelings of anxiety and depression.
METHODS

Study sample.
We utilized data from the Adding Value in Knee Arthroplasty (AViKA) Postoperative Care Navigation Trial, a randomized controlled trial that examined the efficacy of a motiva tional interviewing-based postoperative care navigator, compared with usual care, to improve functional status after TKR for knee OA (8, 9) . The active intervention for this trial was conducted at Brigham and Women's Hospital (BWH), a tertiary care medical center in Boston, MA, from 2010 to 2013, with the 4-year follow-up data collected through December 2017. We included both the active and control arms of the trial in this analysis because both groups had similar profiles of pain relief (9) . At enrollment, all participants spoke English, were 40 years or older at the date of the TKR, and underwent primary TKR for knee OA. Exclusions for AViKA included psychological issues precluding surgery, dementia, nurs ing home residency, and implantation of unicompartmental knee arthroplasty or bilateral TKR (simultaneous, staged, or planned within 6 months). The AViKA Navigator Trial was registered at ClinicalTrials.gov (identifier: NCT01540851) and was approved by the BWH Institutional Review Board. From the original trial cohort (N = 308), 15 subjects did not respond to any follow-up question naires, leaving 293 participants for this analysis. Close to 90% of subjects returned at least four questionnaires, with the majority of subjects (n = 183) returning all six follow-up questionnaires.
Outcome measures. All participants received mailed ques tionnaires at baseline (within 6 weeks prior to TKR), and then at 3-, 6-, 12-, 24-, 36-, and 48-months post-TKR. We ascertained MSK symptomatic areas at baseline and at each follow-up question naire. Participants were asked, "In the past four weeks, to what extent did problems in the following areas limit your activities?" In response, participants could specify the degree of limitation ("none," "a little," or "a lot") for each of the following regions: neck, hands/wrists/arms/shoulders, back, hips, right knee, left knee, and ankles/feet. We did not include the index knee in our assess ment of MSK symptomatic areas. To focus on more clinically rel evant levels of functional limitation, we categorized responses of "none" or "a little" limitation as absence of an MSK symptomatic area and "a lot" as presence of an MSK symptomatic area. This categorization ensured more stringent criteria for the development of a new MSK symptomatic area.
The primary outcome was development of a new MSK symptomatic area in any region after TKR, dichotomized as yes or no. To qualify as a new MSK symptomatic area, the area had to score "none" or "a little" on the baseline questionnaire and "a lot" on at least one follow-up questionnaire. The secondary outcome was first symptomatic area by location (neck, hands/ wrists/arms/shoulders, back, hips, nonindex knee, back, and ankles/feet).
Covariates.
Covariates of interest were assessed at base line and separated into four major categories: general demo graphics, medical comorbidities, MSK comorbidities, and mental health comorbidities. General demographics included age, sex, and body mass index (BMI) (kg/m 2 ). We transformed several covariates from continuous to categorical for ease of clinical inter pretation. Age was categorized as younger than 65 years, 65-75 years, and older than 75 years because the median age of the cohort was 66 years; we wished to examine if an age older than 75 years conferred particularly high risk, and this breakdown was the closest to creating roughly equal tertiles. BMI was categorized as less than 35 and 35 or more because this cutoff is used to differentiate between low risk (class I) versus moderate (class II) to high risk (class III) obesity by the World Health Organization (10) .
Medical comorbidities were extracted through an electronic medical record review via clinic-visit notes and chart problem lists. We calculated the Charlson Comorbidity Index score for each individual participant, which we categorized as 0, 1, and 2 or more (11) . We measured lower-extremity pain and functional limitations using the WOMAC, a validated questionnaire for hip and knee OA that includes a 5-item pain subscale and a 17-item functional lim itation subscale (12) . We transformed WOMAC scores to a 0-to | 375 100-point scale, with 100 indicating the worst score. We dichot omized WOMAC scores at 40 or less or more than 40 to make the scale more interpretable because a score of 40 meant that a respondent endorsed "moderate" to each question about pain or function level (with possible responses being "none," "mild," "moderate," "severe," or "extreme"). We also chose 40 as the cut off because it was the median baseline score for both WOMAC pain and function subscales.
Finally, we assessed mental health status using the five-item Mental Health Inventory (MHI-5), a validated five-item screening tool for anxiety and depression (13) (14) (15) . Scores were summed and transformed to a linear 0-to 100-point scale, with 0 indicating the worst mental health status. This variable was dichotomized to less than 68 and 68 or higher based on established screening cut off criteria for identifying persons likely to have depressive symp toms (13) (14) (15) . To evaluate participants' negative or exaggerated attitudes toward pain, we used the Pain Catastrophizing Scale (PCS), a 13-item score (16, 17) . Because there is no established cutoff for high pain catastrophizing, we used a PCS score of 16 because this corresponded to the 75th percentile of PCS scores in our cohort. This method was used by the creators of the PCS instrument for creating cutoff scores (16) . Also, a previous study analyzing preoperative pain catastrophizing and post-TKR out comes used a similar cutoff score (17) .
Statistical analysis.
Descriptive statistics for the overall cohort were presented as numbers and percentages for all var iables. We compared participants who were included with those excluded from the analysis using χ 2 and Fisher's exact tests for proportions. There were no continuous variables included in the descriptive statistics.
Cumulative incidence and incidence rate. We defined the cumulative incidence of an MSK symptomatic area after TKR as the following: (number of individuals who developed a new symptomatic area in a particular body region)/(number of individ uals without baseline symptoms in that particular body region). We calculated cumulative incidence for each area separately and for at least one involved area. For the cumulative incidence of at least one involved area, the following equation was used: (number of individuals who developed a new symptomatic area in any body region)/(number of individuals with at least one asymptomatic area at baseline). All subjects had the potential of developing another new MSK symptomatic area for any region that had not been previously reported as painful. At baseline, if subjects did not endorse whether a particular MSK-related body site was painful, we coded it as not painful. Using follow-up data, all time points were taken into consideration in determining inci dence. In the rare instance in which a subject did not respond to questions about individual body sites at every time point, these sites were assumed to be not painful.
Censoring occurred at time of outcome, death, date of last completed questionnaire, or the last day of the study. Person-time was defined as the study start date to the time of censoring. We calculated person-time for determining the incidence rate, not as an outcome of interest. Time of outcome was defined as the midway point between a positive questionnaire (reporting new symptomatic area) and the immediate preceding questionnaire. For the outcome of at least one involved area, person-time was truncated at the development of the first new symptomatic area.
The incidence rate of each MSK symptomatic area after TKR was defined as follows: (number of individuals who developed a new symptomatic area in a particular body region)/(total persontime of the population with no baseline symptoms in that par ticular body region). Similarly, the incidence rate of at least one involved area was defined as follows: (number of individuals who developed a new symptomatic area in any body region)/(total per son-time of the population with at least one asymptomatic area at baseline). Total person-time was defined as the study start date to the time of censoring and was summed across all cohort members. Incidence rates with corresponding 95% confidence intervals (CIs) were calculated using the Greenland and Rothman method for each area separately and for the outcome at least one area involved (18) .
Primary analysis: Poisson regression model. To identify baseline factors associated with any incident MSK symp tomatic area after TKR, we used generalized linear mixed models to ac count for within-subject correlations. The first report of a new MSK symptomatic area was coded as incident. If an area be came symptomatic, resolved, and then became symptomatic again, the area was still counted once. Those areas that re mained painful at multiple time points were also only counted once.
To provide risk ratios, we used a modified Poisson regres sion approach with robust error variance (19) . Risk-factor modeling involved the identification of potential covariates via screening based on a two-sided P value less than 0.05, rela tive risk (RR) greater than 1.25, or RR less than 0.8, as deter mined in the bivariate analyses. Covariates that passed the bivariate screen were incorporated simultaneously into the full multivariate Poisson model. To build the parsimonious model, we removed factors one at a time based on least significant P values until all remaining covariates either demonstrated statistical significance by P value or had an RR greater than 1.25 or less than 0.8. Once all covariates met the P value or RR threshold criteria, we considered the parsimonious model complete. Of note, we collapsed the covariate "number of symptomatic areas at baseline" into two categories (0-1 and 2 or more) because univariate analyses suggested a threshold effect at 2.
Secondary analysis: survival analysis. We performed an analysis for time to first incident MSK symptomatic area using Cox proportional hazard regression modeling. Subjects were censored at time of first event or at date of last contact for those not experiencing an incident MSK symptomatic area. Covariate selection for the multivariable Cox regression model was per formed by stepwise selection (the entry and exit criterion was P < 0.15). Because WOMAC pain and function scales are moder ately correlated with one another, we also examined the effect of substituting one with the other on the hazard ratios (HRs) asso ciated with other covariates. We summarized the results as HRs and 95% CIs. Proportional hazards assumptions were evaluated and satisfied for the outcome.
Analyses were conducted using SAS version 9.4 (SAS Insti tute, Inc). Reported P values are two-sided, and P < 0.05 was considered statistically significant.
RESULTS
Patient characteristics.
Baseline characteristics of the cohort are summarized in Table 1 . Among the 308 eligible and enrolled participants, 293 (95%) completed at least 1 follow-up questionnaire and were included in this analysis. The subjects excluded from the analysis (n = 15), compared with the analytic cohort, had similar baseline distributions in age, comorbid condi tions, WOMAC function scores, and measures of psychosocial conditions. Excluded subjects were significantly more likely to report baseline WOMAC pain scores over 40 (77% vs 44%; P = 0.02) and baseline MHI-5 scores less than 68 (54% vs 20%; P = 0.008) compared with subjects in the analytic cohort.
Of the 293 subjects in the analysis sample, the mean (SD) age was 66 (8.2) years, roughly 44% were between the ages of 65 and 75 years old, 61% were women, and 78% had a BMI of less than 35. Nearly two-thirds of the subjects (64%) had a Charl son Comorbidity Index of 0 or 1. Roughly 75% of subjects had no MSK symptomatic areas (besides the index knee) at baseline, whereas 16% had 1 area and 9% had 2 or more areas at baseline. The median baseline WOMAC score for both pain and function was 40. Twenty percent of participants reported baseline symp toms of anxiety and depression, with an MHI-5 score of less than 68. One-quarter of patients demonstrated high pain catastrophiz ing at baseline, with a PCS 16 or more.
Baseline and incident MSK symptomatic areas by region. Table 2 summarizes baseline and incident MSK symp tomatic areas by region for the analytic cohort. Baseline MSK symptomatic areas were most commonly reported in the nonin dex knee (10%), back (10%), and ankles/feet (9%), followed by hands/wrists/arms/shoulders (7%).
The cumulative incidence of MSK symptomatic areas after TKR by location was highest for the nonindex knee (23%), followed by the back (15%), hands/wrists/arms/shoul ders (13%), and hips (13%). Corresponding incidence rates were 6.9 per 100 person-years for the nonindex knee (95% CI 5. 
Secondary analysis: survival analysis.
Based on the multivariable Cox regression model (Figure 1) , preoperative fac tors associated with shorter time to incident MSK symptomatic area included female sex (HR 1.86; 95% CI 1.23-2.82), BMI of 35 or higher (HR 1.69; 95% CI 1.11-2.55), Charlson Comorbidity Index of 2 or more (HR 1.44; 95% CI 0.99-2.09), baseline index knee WOMAC function score greater than 40 (HR 1.75; 95% CI 1.19-2.57), and symptoms consistent with anxiety/depression (MHI-5 less than 68) (HR 1.92; 95% CI 1.26-2.91). These results were consistent with the covariates selected by the final Poisson regression model, except for the WOMAC function score, which replaced the WOMAC pain score. When we reran the Cox regres sion model and inserted WOMAC pain into the model instead of WOMAC function, we obtained similar HRs for female sex, BMI of 35 or higher, Charlson Comorbidity Index, and MHI-5 less than 68; the HR for a WOMAC pain score greater than 40 was 1.63 (95% CI 1.12-2.37).
DISCUSSION
In this study of 293 patients undergoing elective TKR for knee OA, nearly half of participants developed a new MSK symp tomatic area after surgery. Female participants and participants who had a baseline BMI of 35 or higher, Charlson Comorbid ity Index of 2 or more, baseline index knee WOMAC pain score greater than 40, or preoperative symptoms consistent with anxi ety/depression (MHI-5 less than 68) were at higher risk of devel oping incident MSK symptomatic areas. These findings highlight the susceptibility of patients to new MSK symptomatic areas after knee replacement. Moreover, identification of these risk factors for incident MSK symptomatic areas ensures that health Abbreviation: CI, confidence interval; PY, person-years. a For participants with missing data, baseline and/or incident symptomatic areas were presumed to be absent. care providers can focus on vulnerable populations and offer appropriate counseling (ranging from weight to mental health) to best prepare patients for TKR. It is unclear whether incident MSK symptomatic areas, particularly those in the lower extremities, arise as a direct consequence of TKR or are unrelated to the surgery and unmasked by the resolution of a formerly painful index knee. Cumulative inci dence and incidence rates were highest for the nonindex knee and back. It is conceivable that regional pain in these areas arises from changes in gait and asymmetric loading after TKR (20) (21) (22) (23) (24) . Regarding the nonindex knee, multiple studies have noted an association between index and nonindex knee OA. Chitnavis et al (25) reported that among patients who were surveyed shortly after TKR, roughly one-third had bilateral knee replacement, whereas two-fifths of those with unilateral TKR had chronic pain in the con tralateral knee. Shakoor et al (26) found that among recipients of TKR who underwent a second total joint replacement, 92% of the time, it occurred in the contralateral knee. Although degenerative changes likely existed bilaterally prior to TKR, this association sug gests a nonrandom progression of OA in the contralateral knee after arthroplasty TKR (26) .
Other causes of nonindex knee pain include new gait abnor malities; postoperatively, recipients favor the nonoperated limb because of decreased quadriceps strength, decreased knee flex ion, and decreased hip abduction in the operated limb (24, 27, 28) . As for the back, limited knee extension caused by knee OA has been associated with decreased lumbar lordosis and worse lower back pain, a phenomenon termed "knee-spine syndrome" (22, 23) . All of these mechanisms potentially explain why recipients of TKR are susceptible to developing incident nonindex knee and back symptoms postoperatively.
The development of incident upper-extremity MSK symp tomatic areas (ie, neck, hands, wrists, arms, and shoulders) after TKR is more difficult to explain on biomechanical grounds, although upper-extremity problems could stem from use of assistive devices. It is also possible that the MSK symptomatic areas these subjects reported reflect an underlying predisposition to pain reporting, perhaps related to depression and catastrophiz ing, as seen in the analysis. Upper-extremity MSK symptomatic areas, specifically the elbow, were similarly noted by Suri et al (29) in their study of participants with nonsurgical symptomatic knee OA from the Osteoarthritis Initiative. In this study, participants were assessed for knee pain and MSK symptomatic areas at a single time point (time of enrollment). The authors found that ipsilateral elbow pain was associated with higher WOMAC pain subscale scores in the more symptomatic knee. Like our study, this obser vation of an association between knee OA pain severity and elbow pain is suggestive of a generalized pain syndrome in some individ uals with knee OA.
Similarly, multiple studies have demonstrated a positive asso ciation between knee OA and pain sensitization (30, 31) . More specifically, subjects with lower-pressure pain thresholds have been found to have greater OA-associated pain, regardless of disease duration or radiographic severity. This may explain why people undergoing TKR develop incident MSK symptomatic areas elsewhere.
In our study, several baseline covariates were associated with incident MSK symptomatic areas. In the primary analysis, we used a repeated-measures regression model for time to new MSK symptom, and risk factors included female sex, obesity, Charlson Comorbidity Index of 2 or more, baseline index knee WOMAC pain score greater than 40, and symptoms consistent with clinical anxiety/depression. The secondary Cox survival anal ysis identified the same set of risk factors (for shorter time to 4year incident MSK symptomatic area), except that the repeated measures analysis included baseline WOMAC pain and the Cox model included baseline WOMAC function. These two variables are highly correlated (r = 0.83; P < 0.0001). Our findings of an association between baseline WOMAC pain, anxiety or depres sion, and symptomatic nonindex joint counts are consistent with results by Perruccio et al (6) . Although their study was focused on pre-TKR MSK symptomatic areas, they similarly noted that higher baseline WOMAC pain and anxiety/depression scores correlated with higher presurgical symptomatic joint counts (6) .
Our findings also mirror past studies that show that female sex and depression are risk factors for diminished postoperative pain relief and gain of function (2, 3, (32) (33) (34) (35) . Interestingly, obesity, which is associated with surgical com plications in general, has not been implicated in poor knee recovery. Patients with obesity, regardless of BMI severity, are able to achieve similar absolute pain and function scores as patients without obesity within 3-6 months post-TKR (36) (37) (38) . Why patients with obesity were at risk of incident MSK symp tomatic areas in our study is unclear. It is possible that weight- related incident MSK symptomatic areas occur through alternative mechanisms, such as the postoperative asymmet ric loading discussed previously (27, 28) .
We note several limitations. First, the study was conducted at a single tertiary academic center, which may limit generalizability. How ever, the baseline demographics of our cohort, including age and sex, are representative of patients undergoing TKR nationally (1) .
Second, our questionnaire assessed MSK symptomatic areas by region rather than joint, with multiple joints grouped together in some instances (ie, hands/wrists/arms/shoulders and ankles/ feet). This may have led to underreporting of symptomatic joints.
Third, our baseline questionnaires did not assess laterality of symptomatic areas (left vs right); it is possible that incidences and RRs differed based on whether the area was ipsilateral or contralateral to the index knee.
Fourth, our definition of new MSK symptomatic area only included subjects with "a lot" of limitation, whereas those with "a little" limitation were excluded. It is possible that this resulted in underestimation of cumulative incidences and inci dence rates. Our stringent definition resulted in cumulative incidences as high as 15% for the back and 23% for the non index knee. Including participants with "a little" limitation would have led to even higher rates.
Fifth, our study did not differentiate between transient or persistent incident MSK symptomatic areas. The impact of a persistent incident MSK symptomatic area is presumably greater than a transient MSK symptomatic area.
Sixth, we did not analyze the data by individual medical comorbidity but rather by Charlson Comorbidity Index score. As a result, we could not adjust for specific medical comorbidi ties in our assessment of incident MSK symptomatic areas. It is possible that certain medical conditions led to areas of pain or impairment, independent of TKR.
Seventh, a small number of responses regarding MSK pain areas were left blank on follow-up questionnaires, creating ambi guity on whether to consider the response as "no pain" or simply missing. We examined the cumulative incidence and incidence rates of new MSK complaints in each area under both assump tions and found the cumulative incidence differed between the two approaches by less than 1% for each anatomic area.
Eighth, we did not collect sufficient follow-up data on the use of assistive devices, data which may have been helpful in explaining why incident MSK symptoms developed in the upper extremities.
Finally, subjects who were excluded from the study because they had zero follow-up questionnaires were significantly more likely to report worse baseline WOMAC pain scores (greater than 40). Although we cannot definitively determine their impact, it is likely inclusion of these subjects would have led to even higher cumulative incidence and incidence rates of postoperative MSK symptomatic areas.
Incident MSK symptomatic areas, particularly those in the nonindex knee and back, occur in roughly half of recipients of elective TKR in the 4 years following TKR. Predictors of incident MSK symptomatic areas include sex, obesity, medical comor bidities, worse baseline index knee pain scores, and anxiety/ depression. The effects of these incident MSK symptomatic areas on pain, functional status, and quality of life for recipients of TKR have yet to be elucidated. Understanding the prevalence, risk factors, and, ultimately, the impact of incident MSK symp tomatic areas may offer guidance for clinicians on how to opti mize the post-TKR rehabilitation process.
